Selected research
Industry Research
Granisetron Industry Research Report 2026
Market perspective
The global Granisetron market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Granisetron market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Granisetron market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Granisetron market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Granisetron include Kyowa Kirin, Teva, Sandoz, Mylan, Fresenius Kabi, Wockhardt, Taro Pharmaceutical, Natco Pharma and Hikma Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Granisetron market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Granisetron.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Granisetron Market by Company
Kyowa Kirin
Teva
Sandoz
Mylan
Fresenius Kabi
Wockhardt
Taro Pharmaceutical
Natco Pharma
Hikma Pharmaceuticals
Heron Therapeutics
Dr.Reddy's
Cipla
Bluepharma
Aurobindo
APOTEX
Akorn
Granisetron Segment by Type
Injection
Transdermal system
Oral
Granisetron Segment by Application
Chemotherapy
Post operative
Granisetron Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granisetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granisetron and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granisetron.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Granisetron companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Transdermal system
- Oral
Applications
- Chemotherapy
- Post operative
Companies covered
- Kyowa Kirin
- Teva
- Sandoz
- Mylan
- Fresenius Kabi
- Wockhardt
- Taro Pharmaceutical
- Natco Pharma
- Hikma Pharmaceuticals
- Heron Therapeutics
- Dr.Reddy's
- Cipla
- Bluepharma
- Aurobindo
- APOTEX
- Akorn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Granisetron by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Injection
- 2.2.3 Transdermal system
- 2.2.4 Oral
- 2.3 Granisetron by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Chemotherapy
- 2.3.3 Post operative
- 2.4 Assumptions and Limitations
3 Granisetron Breakdown Data by Type
- 3.1 Global Granisetron Historic Market Size by Type (2021-2026)
- 3.2 Global Granisetron Forecasted Market Size by Type (2027-2032)
4 Granisetron Breakdown Data by Application
- 4.1 Global Granisetron Historic Market Size by Application (2021-2026)
- 4.2 Global Granisetron Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Granisetron Market Perspective (2021-2032)
- 5.2 Global Granisetron Growth Trends by Region
- 5.2.1 Global Granisetron Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Granisetron Historic Market Size by Region (2021-2026)
- 5.2.3 Granisetron Forecasted Market Size by Region (2027-2032)
- 5.3 Granisetron Market Dynamics
- 5.3.1 Granisetron Industry Trends
- 5.3.2 Granisetron Market Drivers
- 5.3.3 Granisetron Market Challenges
- 5.3.4 Granisetron Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Granisetron Players by Revenue
- 6.1.1 Global Top Granisetron Players by Revenue (2021-2026)
- 6.1.2 Global Granisetron Revenue Market Share by Players (2021-2026)
- 6.2 Global Granisetron Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Granisetron Head Office and Area Served
- 6.4 Global Granisetron Players, Product Type & Application
- 6.5 Global Granisetron Manufacturers Established Date
- 6.6 Global Granisetron Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Granisetron Market Size (2021-2032)
- 7.2 North America Granisetron Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Granisetron Market Size by Country (2021-2026)
- 7.4 North America Granisetron Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Granisetron Market Size (2021-2032)
- 8.2 Europe Granisetron Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Granisetron Market Size by Country (2021-2026)
- 8.4 Europe Granisetron Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Granisetron Market Size (2021-2032)
- 9.2 Asia-Pacific Granisetron Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Granisetron Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Granisetron Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Granisetron Market Size (2021-2032)
- 10.2 South America Granisetron Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Granisetron Market Size by Country (2021-2026)
- 10.4 South America Granisetron Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Granisetron Market Size (2021-2032)
- 11.2 Middle East & Africa Granisetron Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Granisetron Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Granisetron Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Kyowa Kirin
- 12.1.1 Kyowa Kirin Company Information
- 12.1.2 Kyowa Kirin Business Overview
- 12.1.3 Kyowa Kirin Revenue in Granisetron Business (2021-2026)
- 12.1.4 Kyowa Kirin Granisetron Product Portfolio
- 12.1.5 Kyowa Kirin Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Granisetron Business (2021-2026)
- 12.2.4 Teva Granisetron Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sandoz
- 12.3.1 Sandoz Company Information
- 12.3.2 Sandoz Business Overview
- 12.3.3 Sandoz Revenue in Granisetron Business (2021-2026)
- 12.3.4 Sandoz Granisetron Product Portfolio
- 12.3.5 Sandoz Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Granisetron Business (2021-2026)
- 12.4.4 Mylan Granisetron Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Fresenius Kabi
- 12.5.1 Fresenius Kabi Company Information
- 12.5.2 Fresenius Kabi Business Overview
- 12.5.3 Fresenius Kabi Revenue in Granisetron Business (2021-2026)
- 12.5.4 Fresenius Kabi Granisetron Product Portfolio
- 12.5.5 Fresenius Kabi Recent Developments
- 12.6 Wockhardt
- 12.6.1 Wockhardt Company Information
- 12.6.2 Wockhardt Business Overview
- 12.6.3 Wockhardt Revenue in Granisetron Business (2021-2026)
- 12.6.4 Wockhardt Granisetron Product Portfolio
- 12.6.5 Wockhardt Recent Developments
- 12.7 Taro Pharmaceutical
- 12.7.1 Taro Pharmaceutical Company Information
- 12.7.2 Taro Pharmaceutical Business Overview
- 12.7.3 Taro Pharmaceutical Revenue in Granisetron Business (2021-2026)
- 12.7.4 Taro Pharmaceutical Granisetron Product Portfolio
- 12.7.5 Taro Pharmaceutical Recent Developments
- 12.8 Natco Pharma
- 12.8.1 Natco Pharma Company Information
- 12.8.2 Natco Pharma Business Overview
- 12.8.3 Natco Pharma Revenue in Granisetron Business (2021-2026)
- 12.8.4 Natco Pharma Granisetron Product Portfolio
- 12.8.5 Natco Pharma Recent Developments
- 12.9 Hikma Pharmaceuticals
- 12.9.1 Hikma Pharmaceuticals Company Information
- 12.9.2 Hikma Pharmaceuticals Business Overview
- 12.9.3 Hikma Pharmaceuticals Revenue in Granisetron Business (2021-2026)
- 12.9.4 Hikma Pharmaceuticals Granisetron Product Portfolio
- 12.9.5 Hikma Pharmaceuticals Recent Developments
- 12.10 Heron Therapeutics
- 12.10.1 Heron Therapeutics Company Information
- 12.10.2 Heron Therapeutics Business Overview
- 12.10.3 Heron Therapeutics Revenue in Granisetron Business (2021-2026)
- 12.10.4 Heron Therapeutics Granisetron Product Portfolio
- 12.10.5 Heron Therapeutics Recent Developments
- 12.11 Dr.Reddy's
- 12.11.1 Dr.Reddy's Company Information
- 12.11.2 Dr.Reddy's Business Overview
- 12.11.3 Dr.Reddy's Revenue in Granisetron Business (2021-2026)
- 12.11.4 Dr.Reddy's Granisetron Product Portfolio
- 12.11.5 Dr.Reddy's Recent Developments
- 12.12 Cipla
- 12.12.1 Cipla Company Information
- 12.12.2 Cipla Business Overview
- 12.12.3 Cipla Revenue in Granisetron Business (2021-2026)
- 12.12.4 Cipla Granisetron Product Portfolio
- 12.12.5 Cipla Recent Developments
- 12.13 Bluepharma
- 12.13.1 Bluepharma Company Information
- 12.13.2 Bluepharma Business Overview
- 12.13.3 Bluepharma Revenue in Granisetron Business (2021-2026)
- 12.13.4 Bluepharma Granisetron Product Portfolio
- 12.13.5 Bluepharma Recent Developments
- 12.14 Aurobindo
- 12.14.1 Aurobindo Company Information
- 12.14.2 Aurobindo Business Overview
- 12.14.3 Aurobindo Revenue in Granisetron Business (2021-2026)
- 12.14.4 Aurobindo Granisetron Product Portfolio
- 12.14.5 Aurobindo Recent Developments
- 12.15 APOTEX
- 12.15.1 APOTEX Company Information
- 12.15.2 APOTEX Business Overview
- 12.15.3 APOTEX Revenue in Granisetron Business (2021-2026)
- 12.15.4 APOTEX Granisetron Product Portfolio
- 12.15.5 APOTEX Recent Developments
- 12.16 Akorn
- 12.16.1 Akorn Company Information
- 12.16.2 Akorn Business Overview
- 12.16.3 Akorn Revenue in Granisetron Business (2021-2026)
- 12.16.4 Akorn Granisetron Product Portfolio
- 12.16.5 Akorn Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst